Prevalence of pretreatment HIV drug resistance in Mwanza, Tanzania
Please always quote using this URN: urn:nbn:de:bvb:20-opus-227124
- Background: In a 2008-10 study, we found a pretreatment HIV drug resistance (PDR) prevalence of 18.2% in patients at Bugando Medical Centre (BMC) in Mwanza, Tanzania. Objectives: To determine the prevalence of PDR and transmitted HIV drug resistance (TDR) in patients visiting the BMC from 2013 to 2015. Methods: Adult outpatients were sequentially enrolled into two groups, separated by whether they were initiating ART. Previous exposure to antiretroviral drugs, except for prevention of mother-to-child transmission, was an exclusionBackground: In a 2008-10 study, we found a pretreatment HIV drug resistance (PDR) prevalence of 18.2% in patients at Bugando Medical Centre (BMC) in Mwanza, Tanzania. Objectives: To determine the prevalence of PDR and transmitted HIV drug resistance (TDR) in patients visiting the BMC from 2013 to 2015. Methods: Adult outpatients were sequentially enrolled into two groups, separated by whether they were initiating ART. Previous exposure to antiretroviral drugs, except for prevention of mother-to-child transmission, was an exclusion criterion. HIV pol sequences were analysed according to WHO guidelines for surveillance of PDR and TDR. Results: Two hundred and thirty-five sequences were analysed (138 ART initiators, 97 non-initiators). The prevalence of PDR was 4.7% (95% CI 2.6%-8.2%) overall, 3.1% (95% CI 1.1%-8.7%) for non-initiators and 5.8% (95% CI 3.0%-11.0%) for ART initiators. PDR to NNRTIs and nucleoside or nucelotide reverse transcriptase inhibitors was found in 3.0% (95% CI 1.5%-6.0%) and 1.7% (95% CI 0.7%-4.3%) of patients, respectively. Resistance to PIs was not observed. The prevalence of TDR was 6.0% (95% CI 3.6%-9.8%). Conclusions: Prevalence of PDR significantly decreased compared with 2008-10 and was below the WHO-defined threshold for triggering a public health response. National and systematic surveillance is needed to inform Tanzania's public health strategy.…
Author: | Ladius Rudovick, Jan M. Brauner, Johanna Englert, Carolina Seemann, Karina Plugaru, Benson R. Kidenya, Samuel E. Kalluvya, Carsten Scheller, Christa Kasang |
---|---|
URN: | urn:nbn:de:bvb:20-opus-227124 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Institut für Virologie und Immunbiologie |
Language: | English |
Parent Title (English): | Journal of Antimicrobial Chemotherapy |
Year of Completion: | 2018 |
Volume: | 73 |
Issue: | 12 |
Pagenumber: | 3476-3481 |
Source: | J Antimicrob Chemother 2018; 73: 3476–3481 |
DOI: | https://doi.org/10.1093/jac/dky332 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | HIV; adult; anti-hiv agents; anti-retroviral agents; child; exclusion criteria; guidelines; medical; mothers; non-nucleoside reverse transcriptase inhibitors; nucleosides; outpatients; prevention; public health medicine; reverse transcriptase inhibitors; surveillance; tanzania; world health organization |
Release Date: | 2023/01/30 |
Licence (German): | CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International |